India approved Qdenga, its first dengue vaccine, amidst rising cases and expanding mosquito habitats. While its design improves upon previous attempts, concerns persist. Protection varies, particularly against DENV-3 and DENV-4, crucial given increasing DENV-3 prevalence. The two-dose, three-month schedule complicates rollout, especially for migrant workers, and initial protection is uneven. Potential "negative efficacy" against DENV-3 hospitalisation in seronegative children raises flags. High costs are a barrier for vulnerable communities, necessitating government price negotiation. Effective administration demands vigilance, as developing the vaccine was only half the battle.